Nkarta’s (NKTX) “Buy” Rating Reaffirmed at HC Wainwright

Nkarta (NASDAQ:NKTX – Get Rating)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a report issued on Friday, MarketBeat Ratings reports. They presently have a $30.00 price target on the stock, down from their prior price target of $34.00.

Separately, Oppenheimer downgraded Nkarta from an “outperform” rating to a “market perform” rating in a research note on Thursday, December 22nd. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat.com, Nkarta has an average rating of “Moderate Buy” and an average target price of $28.67.

Nkarta Price Performance

NKTX opened at $3.84 on Friday. The business’s 50-day moving average price is $4.91 and its two-hundred day moving average price is $8.65. Nkarta has a 1 year low of $3.57 and a 1 year high of $20.35. The company has a market capitalization of $187.43 million, a price-to-earnings ratio of -1.44 and a beta of 0.18.

Hedge Funds Weigh In On Nkarta

Hedge funds have recently modified their holdings of the stock. T. Rowe Price Investment Management Inc. grew its holdings in Nkarta by 18.6% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 4,749,101 shares of the company’s stock worth $28,448,000 after purchasing an additional 745,757 shares during the period. Price T Rowe Associates Inc. MD grew its holdings in Nkarta by 64.4% during the second quarter. Price T Rowe Associates Inc. MD now owns 3,879,662 shares of the company’s stock worth $47,797,000 after purchasing an additional 1,520,473 shares during the period. State Street Corp grew its holdings in Nkarta by 68.9% during the third quarter. State Street Corp now owns 2,296,476 shares of the company’s stock worth $30,222,000 after purchasing an additional 936,861 shares during the period. BlackRock Inc. grew its holdings in Nkarta by 0.8% during the third quarter. BlackRock Inc. now owns 2,275,852 shares of the company’s stock worth $29,950,000 after purchasing an additional 17,190 shares during the period. Finally, Tang Capital Management LLC grew its holdings in Nkarta by 182.1% during the fourth quarter. Tang Capital Management LLC now owns 1,870,000 shares of the company’s stock worth $11,201,000 after purchasing an additional 1,207,128 shares during the period. Institutional investors own 87.22% of the company’s stock.

About Nkarta

(Get Rating)

Nkarta, Inc, a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells.